Abstract:The nucleotide-binding, oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease. NLRP3 is activated by a diverse range of inflammation-instigating signals known as pathogen associated molecular patterns and danger associated molecular patterns. Upon activation, NLRP3 oligomerizes and recruits partner proteins to form a supramolecular platform to process the maturation and release of interleukin (IL)-1 β , IL-18, and gasdermin D, major mediators of inflammation and inflammatory cell death termed pyroptosis. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide range of disease conditions, including chronic inflammatory disease that are associated with lifestyle and dietary changes, aging, and environmental exposures, and have become the leading cause of death worldwide. Pharmacological targeting of NLRP3 and signaling demonstrated promising efficacy in ameliorating a list of disease conditions in animal models. These findings underscore the potential and importance of NLRP3 as a druggable target for treating a range of diseases. In this review, recent progress in understanding the structure and mechanism of action of the NLRP3 inflammasome is discussed with focus on pharmacological inhibition of NLRP3 by small molecule inhibitors. New structural and mechanistic insights into NLRP3 activation and inhibitor-NLRP3 interactions would aid in the rational design and pharmacological evaluation of NLRP3 inhibitors for treatment of human disease. Significance Statement The NLRP3 inflammasome plays central role in innate immune sensing and control of inflammation. Pharmacological inhibition of NLRP3 demonstrated promising efficacy in a range of diseases in animal models. Recent elucidation of the structure and inhibitor binding of NLRP3 generated new insights into its mode of action and inhibitor-NLRP3 interaction at molecular levels, providing new framework for developing small chemical inhibitors of NLRP3 with improved efficacy and specificity against chronic disease that has become major health concerns worldwide.

Author Correction: Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Corrigendum: A Synthetic Small Molecule F240B Decreases NLRP3 Inflammasome Activation by Autophagy Induction

Corrigendum: Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes In Vitro

Author Correction: STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

Inflammasome components as new therapeutic targets in inflammatory disease

Publisher Correction: Inhibition of LTβR Signalling Activates WNT-induced Regeneration in Lung

Author Correction: Structural insights into the activation of metabotropic glutamate receptors

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]

Corrigendum: NLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia via IL-1β Pathway

Targeting the NLRP3 inflammasome in inflammatory diseases

Author Correction: Evaluating drug targets through human loss-of-function genetic variation

Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential

Retracted: In Silico Structural and Functional Analyses of NLRP3 Inflammasomes to Provide Insights for Treating Neurodegenerative Diseases

Author Correction: NMNAT2 is a druggable target to drive neuronal NAD production

NLRP3 monomer Functional Dynamics: from the Effects of Allosteric Binding to Implications for Drug Design

Spatiotemporal proteomic profiling of cellular responses to NLRP3 agonists

Author Correction: NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development

Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules

Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance